Results of EBOVAC1 Phase 1 trials in Africa published

The results of EBOVAC1’s Phase 1 trials in Africa have been published in the Journal of Infectious Diseases. The results of the studies in Kenya, Tanzania and Uganda indicate that the two-dose vaccine regimen (Ad26.ZEBOV/ MVA-BN-Filo) is well-tolerated and highly immunogenic against Ebola in healthy adults.

The EBOVAC1 consortium has implemented three Phase 1 trials of the vaccine regimen in Oxford, UK; Nairobi, Kenya; and Entebbe, Uganda/ Mwanza, Tanzania.

The results of the VAC52150EBL1003 study in Kenya can be found here.
The results of the VAC52150EBL1004 study in Uganda and Tanzania can be found here.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu